StockNews.AI
ASRT
StockNews.AI
5 hrs

NASDAQ: SPPI CLASS ACTION NOTICE: Berger Montague Encourages Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action

1. Securities fraud claims against Spectrum Pharmaceuticals are being investigated. 2. Investors can seek lead plaintiff status by September 24, 2025. 3. Spectrum's shares were delisted after merging with Assertio Holdings (ASRT). 4. Allegations include misleading statements on the Pinnacle Study. 5. The legal action may affect the merger's perception and investor confidence.

11m saved
Insight
Article

FAQ

Why Neutral?

The article mainly discusses litigation against Spectrum without directly affecting ASRT's operations. Historical cases show that legal challenges can create market hesitation but not adversely impact the surviving company's stock if they are unrelated or isolated.

How important is it?

The relevance to ASRT is significant due to the merger with Spectrum, but the actual impact on ASRT's stock is mitigated by the separation of investigations and ongoing operations.

Why Short Term?

The investigation may create immediate investor volatility but is unlikely to have a long-term impact on ASRT. Similar situations have shown that such news often results in short-lived reactions in the market.

Related Companies

SPPI

PHILADELPHIA, Aug. 19, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period").

Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

Spectrum is a biopharmaceutical company focused on oncology treatments.

The class action lawsuit alleges that Spectrum made false or misleading statements to investors regarding its Pinnacle Study, a clinical trial involving poziotinib, a drug intended to treat certain lung cancer patients.

Spectrum shares were delisted following the Company's merger with Assertio Holdings, Inc. (NASDAQ:ASRT).

If you are a Spectrum investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.

About Berger Montague

Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

For more information or to discuss your rights, please contact:

Andrew Abramowitz, Senior Counsel

Berger Montague

(215) 875-3015

aabramowitz@bergermontague.com

Caitlin Adorni

Berger Montague

(267) 764-4865

cadorni@bergermontague.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nasdaq-sppi-class-action-notice-berger-montague-encourages-spectrum-pharmaceuticals-nasdaq-sppi-investors-to-inquire-about-a-securities-fraud-class-action-302533702.html

SOURCE Berger Montague

Related News